EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

THE EFFICIENCY OF RIVAROXABAN WITH OR WITHOUT ASPIRIN AS ANTITHROMBOTIC THERAPY FOR MANAGEMENT OF CARDIOVASCULAR RISK

Mahmudul Hasan*, Mohammad Rashedul Hasan and Monir Uddin Ahamed

ABSTRACT

Background: Cardiovascular diseases is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of platelets and coagulation proteins. Factor Xa inhibitors and aspirin each reduce thrombotic events but have not yet been tested in combination or against each other in patients with stable Cardiovascular diseases. Objective: In this study our main goal is to evaluate the efficiency of Rivaroxaban with or without aspirin for management of cardiovascular risk. Method: This was a case control study was conducted from January 2020 to January 2021 at tertiary hospital. A random sample of 100 rural and urban individual (age ≥41 years) were included in this study. The eligible participants were informed about the objectives of the study.. Eligible patients with coronary artery disease had to have had a myocardial infarction in the past 10 years, multi-vessel coronary artery disease, history of stable or unstable angina, previous multi-vessel percutaneous coronary intervention, or previous multi-vessel coronary artery bypass graft surgery. After a 30-day run in period, those patients who were receive rivaroxaban (2·5 mg orally twice a day) plus aspirin (75 mg once a day) regarded as a case group, n=50, and those who received aspirin alone (75 mg orally once a day) regarded as acontrol group, n=50. Results: During the study, most of the patients belongs to (41-50) age group, 71%.HTN cases seen in 65%, followed by IHD cases seen in 25%, MI seen in 70% cases, Percutaneous coronary intervention seen in 60%, stroke in 7% cases, heart failure in 25%cases, DM seen in 30% cases and asthma seen in 10% cases. In the study, Stroke, MI and hear failure occurred less frequently in patients in the low-dose rivaroxaban plus aspirin group than in the aspirin alone group. However, in 5% cases major bleeding seen in low-dose rivaroxaban plus aspirin group followed by 3% cases were fatal, 2% were ISTH major bleeding and minor bleeding. Whereas in control group major bleeding cases were quite low, 3%. Followed by 1% cases were fatal, 1% were ISTH major bleeding and minor bleeding. Conclusion: In patients with stable cardiovascular disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding. There was no significant increase in intracranial bleeding or other critical organ bleeding. However apart from some downwards addition of rivaroxaban to aspirin has the potential to substantially reduce morbidity and mortality from cardiovascular disease.

Keywords: Cardiovascular diseases (CVD), Rivaroxaban, Antithrombin therapy.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • EJPMR: JANUARY ISSUE PUBLISHED

    JANUARY issue has been successfully launched on 1 JANUARY 2023.

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 January 2023 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database